Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175786 | 0.87 | SNCA (0.67) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL27559263 | 0.87 | SNCA (0.52) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL6281110 | 0.84 | SNCA (0.56) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL12228311 | 0.84 | SNCA (0.56) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL10590383 | 0.83 | SNCA (0.55) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL18148926 | 0.83 | LOXL2 (0.56) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL10356047 | 0.83 | SNCA (0.55) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL4433115 | 0.82 | SNCA (0.58) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL461801 | 0.82 | SNCA (0.61) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL17386391 | 0.82 | SNCA (0.61) | SNCACYP3A4ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528901-B9 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| EP-2938612-A1 | PROTEIN KINASE INHIBITORS | OriBase Pharma (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2528901-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-8791272-B2 | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| WO-2014102376-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
| EP-2528901-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092140-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| EP-0915843-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSES | SMITHKLINE BEECHAM PLC (GB) | 1999-05-19 | — | — | EP | disclosed |
| EP-0840725-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997041098-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-11-06 | — | — | WO | disclosed |
| EP-0799200-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1997002242-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-01-23 | — | — | WO | disclosed |
| US-5580865-A | ELASTASE INHIBITORS; ANTIINFLAMMATORY AGENTS; DEGENERATIVE DISEASES; EMPHYSEMA, ADULT RESPIRATORY DISTRESS SYNDROME, RHEUMATIC FEVER, SPONDYLITIS, GOUT, LUPUS AND PSORIASIS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1996-12-03 | — | — | US | disclosed |
| WO-1996019451-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | disclosed |
| EP-0564835-A2 | 2,2-Disubstituted cephem sulphones | PHARMACIA S.p.A. (IT) | 1993-10-13 | — | — | EP | disclosed |
| US-4288607-A | USEFUL IN UNSATURATED POLYESTERS AND AS FIRE RETARDANTS | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1981-09-08 | — | — | US | disclosed |
| US-4152511-A | FIRE-RETARDANT MOLDING MATERIALS CONTAINING CHLORINE OR BROMINE | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | SNCA 4070/4885CYP3A4 3437/4885ALDH1A1 3646/4885 |
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH3 | SNCA 4397/4885CYP3A4 903/4885ALDH1A1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.